Confounding by indication is a vexing problem, especially in evaluating treatment effects using observational data, since treatment decisions are often related to disease severity, prognosis, and frailty. To compare the ability of the instrumental variable (IV) approach with a new instrument based on the local-area practice style and risk adjustment methods, including conventional multivariate regression and propensity score adjustment, to reduce confounding by indication, the authors investigated the effects of long-term control (LTC) therapy on the occurrence of acute asthma exacerbation events among children and young adults with incident and uncontrolled persistent asthma, using Iowa Medicaid claims files from 1997-1999. Established evidence from clinical trials has demonstrated the protective benefits of LTC therapy for persistent asthma. Among patients identified (n ¼ 4,275), those with higher asthma severity at baseline were more likely to receive LTC therapy. The multivariate regression and propensity score adjustment methods suggested that LTC therapy had no effect on the occurrence of acute exacerbation events. Estimates from the new IV approach showed that LTC therapy significantly decreased the occurrence of acute exacerbation events, which is consistent with established clinical evidence. The authors discuss how to interpret estimates from the risk adjustment and IV methods when the treatment effect is heterogeneous.
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Confounding is a major threat to the validity of observational studies when confounders are not adequately measured or adjusted for. In studies designed to assess treatment effectiveness, confounders are factors associated with both treatment choice and outcome (1, 2) . Confounding by indication is a particularly difficult problem in evaluating the effects of treatment using observational data, because data on the severity of the underlying medical condition, frailty, and other individual patient prognostic factors that influence physicians' treatment decisions are often unavailable in observational health-care utilization databases (3) (4) (5) .
To reduce confounding by indication, instrumental variable (IV) approaches and several risk adjustment (RA) methods, including multivariable regression analysis and propensity score (PS) adjustment, have been used to estimate treatment effects (3, (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, both RA and IV methods require strong assumptions. RA methods assume that all confounders are measured or that unmeasured confounders can be ignored to yield unbiased estimates (15, 16) . The ''instruments'' in IV analysis must be associated with treatment choice and are assumed to be unrelated either to outcome directly or to unmeasured confounders; thus, they essentially serve as natural experiments of treatment choice (17) (18) (19) . Instruments with weak associations with treatment choice may cause inflated standard errors and erroneous conclusions regarding treatment effects (9, 20, 21) . Brookhart et al. (13) showed that using instruments based on physician-level prescribing preferences substantially reduced bias associated with unmeasured confounding as compared with conventional RA methods in evaluating intended drug effects. A new IV has been developed using measures of local-area practice styles that demonstrates a stronger association with treatment choice than the physician-level instrument and also balances measured confounders as well as the physician-level instrument (22) .
The purpose of this study was to compare the ability of the IV approach with the new instrument based on the local-area practice style and RA methods in reducing confounding by indication through investigation of the effects of long-term control (LTC) therapy on acute asthma exacerbation among Iowa Medicaid patients with incident and uncontrolled persistent asthma in the late 1990s. Because this period was prior to the development of national clinical guidelines promoting the use of LTC therapy for persistent asthma, considerable variation in physicians' discretion in LTC therapy use was expected. In this article, we describe our study and then discuss the interpretation of RA and IV estimates in light of the heterogeneity of treatment effects.
Recent national guidelines recommend the use of LTC therapies, including inhaled corticosteroids, the combination of inhaled corticosteroids and long-acting b agonists, leukotriene modifiers, and mast cell stabilizers, to control and manage persistent asthma (23) (24) (25) . The guidelines are based on established clinical trial evidence from the past 20 years on the use of antiinflammatory LTC therapy in reducing symptoms, acute exacerbation, emergency room visits, and hospitalization among patients with persistent asthma (26, 27) . In contrast to the clinical trial evidence, many observational studies have shown that the use of LTC therapy is associated with increased risk of acute asthma exacerbation events using multivariate RA methods (28) (29) (30) (31) . It is likely that these studies were plagued by confounding by indication, since LTC therapies in practice were more likely to be prescribed to asthma patients with more severe symptoms and worse pulmonary function-characteristics that were undocumented in the observational health-care utilization data. As with other observational studies on this question, the Medicaid claims data used in this study did not contain measures of asthma symptoms, impairment, or pulmonary function that would reveal the exact severity of asthma among individual patients at the time the treatment choice was made. Thus, we contrasted the ability of the new IV approach and RA models to estimate the protective effects of LTC therapy for persistent asthma in situations where treatment effects are known and unmeasured confounding by indication would probably bias estimates of LTC therapy effects downward.
MATERIALS AND METHODS

Study population and data
We identified Medicaid patients aged 3-25 years with an asthma diagnosis (International Classification of Diseases, Ninth Revision (ICD-9), code 493.x) and at least 1 filled prescription for any asthma medication, including LTC therapy and short-acting b agonists (SABA), during the study period in 1997-1999. A cohort of patients with new-onset and uncontrolled persistent asthma was formed using Iowa Medicaid enrollment, inpatient, outpatient, physician office, and prescription claims files.
We identified patients who had had uncontrolled asthma symptoms more often than 2 days per week during the past month-the definition of ''persistent asthma'' according to National Institutes of Health (Expert Panel Report 3) guidelines for the diagnosis and management of asthma (25) . This rate of symptoms (>2 days/week) represents uncontrolled persistent asthma if it is not explained solely by an acute triggering event (e.g., upper respiratory tract infection). A case of incident and uncontrolled persistent asthma was defined as an individual 1) whose consecutive SABA prescription refills corresponded to a calculated average use of >2 days per week (4 puffs/day for quick relief of symptoms) for !30 days and 2) who did not have an LTC therapy prescription or SABA prescription with a calculated use of >2 days per week between refills in the prior 3 months. The date of the first SABA prescription during the period that met the case definition was set as the index date. A patient was designated as having initiated treatment with LTC therapy if the patient filled 1 or more prescriptions for LTC therapy within 30 days after the index date. The 30-day cutoff was chosen because the severity of asthma may fluctuate over time and is required to be reassessed after 4 weeks (25) . Included patients must also have been continuously enrolled in Medicaid for at least 3 months prior to and 3 months after the index date. Patients were excluded if they had a diagnosis code in the claims file for cystic fibrosis (ICD-9 code 277.0), bronchopulmonary dysplasia (ICD-9 code 770.7), or tracheomalacia (ICD-9 code 748.3) at any time during the study period. National drug codes in the prescription claims file were used to identify asthma medications. When prescription claims were for different dosages of SABA, SABA dose was converted to a 200-puff canister inhaler-equivalent dose (32) .
IV based on local-area practice styles
We applied the new IV developed by generating zip codespecific LTC therapy prescribing-style measures based on the area treatment ratio (ATR) for persistent asthma patients within driving-time areas around each patient's residential zip code-the Driving Area for Clinical Care (DACC) (22) . For each residential zip code, the DACC method collects all patients with the same medical condition/diagnosis living in zip codes within driving distance of the residential zip code. The driving time around each zip code is increased until a minimum number of patients with the diagnosis are identified in zip codes around the original zip code. As a result, the driving times required to reach the minimum patient threshold will vary across zip codes, which is needed to account for urban/rural differences in health-care access across zip codes, since patients in rural areas routinely drive farther for health care. Web Appendix 1 (available on the Journal's website (http://aje.oxfordjournals.org/)) provides additional explanation of the DACC algorithm. ATRs for each zip code are calculated as the ratio of the observed treatment rate to the expected treatment rate in the DACC around the zip code. The expected treatment rate is generated as the sum of the probabilities of receiving treatment from a multivariable logistic regression analysis divided by the total number of patients identified in the DACC around each zip code (22) (see Web Appendix 2). In this study, we used 20 as the minimum number of patients identified as cases of persistent asthma to define the DACC for a specific zip code (22) . Each patient was assigned the ATR of his/her residential zip code.
A treatment ratio greater than 1 indicates an area practice style that uses more LTC therapy for persistent asthma patients than would be expected on average. The larger the ATR, the stronger the preference in an area for use of LTC therapy. To create IV measures, we assessed the distribution of ATRs and found the ATR values that provided median, tertile, and quartile cutoffs (Web Figure 1) . Each patient was then uniquely assigned to ATR median, tertile, and quartile groups using these cutoffs, based on the ATR of his/her residential zip code.
Outcome
The outcome was defined as the occurrence of acute asthma exacerbation events, including emergency room visits or hospitalization with asthma as the primary diagnosis or use of oral corticosteroids during the 2-month follow-up period after the 30-day treatment initiation period. The dependent variable of the outcome measure was a binary variable with 1 for having event(s) and 0 for having no event(s).
Covariates
Patient demographic characteristics, including age, gender, and poverty level on the index date, were determined from Iowa Medicaid enrollment files. Patient clinical characteristics, determined using prescription and medical claims files, included the total number of physician office visits with asthma as the primary diagnosis and the occurrence of acute asthma exacerbation events within the 3 months prior to the index date; the occurrence of acute asthma exacerbation events and the number of physician office visits with asthma as the primary diagnosis within 1 month prior to the index date; and diagnosis of upper respiratory tract infection (ICD-9 codes 460.x-465.x), acute bronchitis or bronchiolitis (ICD-9 code 466.x), acute sinusitis (ICD-9 code 461.x), chronic sinusitis (ICD-9 code 473.x), chronic bronchitis (ICD-9 code 491.x), or allergic rhinitis (ICD-9 code 493.x) within 1 month prior to the index date. To approximate the severity level of persistent asthma before the treatment was initiated, we also measured the average use of SABA (puffs/week) for the first SABA prescription that met the case definition. Other measured covariates included dummy variables for the year (reference: 1997) and season (reference: winter) of the index date.
Analysis
To assess the effects of LTC therapy using the new IV, we first created maps of the LTC ATR and outcome event rate using the DACC method at the zip code level and contrasted the maps. If the instrument captured the protective effects of LTC therapy, areas with greater use of LTC therapy would have lower outcome event rates, on average. We used the standard 2-stage least squares models for IVanalyses because 2-stage least squares regressions are based on the fewest assumptions and generate the most consistent IV estimates, even when the treatment and outcome are binary variables (12, 17, 33, 34) . We used median, tertile, and quartile groups of LTC ATR as the instruments in the 2-stage least squares models to assess whether results would be sensitive to the instrument specification using different ATR cutoffs. We tested whether the instruments in each specification were strongly associated with the use of LTC therapy. Larger partial F statistics of instruments indicate a stronger relation between instruments and treatment choice, and partial F statistics greater than 10 are considered not weak in the IV literature (20) . We then used overidentification tests (Sargan test and Basmann 
À0.3
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Am J Epidemiol. 2012;175 (11) (12, 22, 37) . We calculated the summary percentage change in the imbalance of covariates when stratified by instruments versus actual treatment using the Mahalanobis distance, which corrects for observed covariance among measured covariates (22, 38, 39) .
To assess the effects of LTC therapy using the RA methods, we used linear probability regression models to obtain estimates of an absolute outcome event risk difference that were consistent in interpretation with the estimates from the 2-stage least squares models in the IV analyses (37) . In the multivariate regression model, we adjusted all measured covariates to estimate the outcome events among patients who received LTC treatment versus those who did not. Next, we applied 3 PS adjustment methods for the analyses (8, 40) . Using multivariate logistic regression, we estimated the PS for receiving LTC therapy as a function of the measured covariates. The ranges of PS between treated and untreated patients overlapped considerably (Figure 1) . Therefore, we only had to trim 16 patients (0.37%) who were outside the commonly supported PS range from the cohort for PS adjustment analyses. With the first PS method, we used the continuous PS as a method of adjustment in the regression model. With the second PS method, we divided the cohort into PS quintiles and adjusted for PS quintiles in the regression model, with the lowest quintile used as the reference category. Lastly, we estimated the treatment effectiveness using the nearest-neighbor matching method to match treated patients with untreated patients with the closest PS and bootstrapped 95% confidence intervals from 1,000 iterations with replacement (41) .
All analyses were conducted using SAS, version 9.2 (SAS Institute Inc., Cary, North Carolina), and STATA 9.2 (StataCorp LP, College Station, Texas).
RESULTS
There were 4,275 Iowa Medicaid patients aged 3-25 years who met the case definition and the inclusion and exclusion criteria. Among those patients, 787 (18.4%) had prescriptions for LTC therapy filled within 1 month after the index date, with inhaled corticosteroids accounting for 75% of the LTC treatments. Table 1 shows that patients treated with LTC therapy had much greater asthma severity than patients who did not receive LTC therapy. At baseline, patients who had LTC therapy had more physician office visits with asthma as the primary diagnosis, had more acute asthma exacerbation events, and had more asthma symptoms requiring the use of SABA before treatment initiation. The rate of LTC therapy use in the fourth quartile of the ATR was 28.3%, which was a 3-fold increase (18.8 percentage points) from the 9.5% rate of LTC therapy use in the first quartile of the ATR. Compared with grouping patients by actual treatment choice, patient baseline characteristics were well balanced between the patients grouped by the practice-style-based instruments. The practice-style-based instruments significantly reduced covariate imbalance based on the summary change measure. When patients were grouped by the median value (upper and lower groups) and by the third and first tertiles of the ATR, there were 1.9-fold and 2.5-fold increases in the rate of LTC therapy use, respectively, and patient baseline characteristics were well balanced (69% and 62% reductions in covariate imbalance, respectively) between groups. Figure 2 provides a map of ATRs at the zip code level and reveals considerable practice-style variation in the use of LTC therapies. In addition, areas with higher use of LTC therapy generally had lower rates of acute asthma exacerbation events during follow-up. Table 2 shows the estimates of LTC therapy effectiveness from the unadjusted model, the multivariate RA model, the PS adjustment models, and the 2-stage least squares IV models. The unadjusted model showed that use of LTC therapy was significantly associated with more acute asthma exacerbation events (3 more events per 100 patients). The multivariateadjusted model and all 3 PS adjustment models found no association between LTC therapy and the occurrence of acute exacerbation events. Estimates from the IV models with different IV specifications all showed that use of LTC therapy was associated with significantly fewer events (approximately 16 fewer events per 100 patients) within 2 months of followup. The instruments were significantly and strongly associated with use of LTC therapy, and the null hypothesis that the instruments were not associated with the outcomes was not rejected.
DISCUSSION
Our study contrasted the abilities of standard RA and IV methods to alleviate confounding by indication among patients with persistent asthma, using a new instrument based on measures of local-area practice styles by DACC. Established evidence from randomized clinical trials has demonstrated that LTC therapies reduce acute asthma exacerbation in patients with persistent asthma (23, (25) (26) (27) . In contrast, our unadjusted analysis showed that LTC therapy was associated with more acute asthma exacerbation events. However, patients who initiated LTC therapy had a more severe asthma status at baseline, which is typical of confounding by indication. Information on the exact severity and impairment level of asthma symptoms (e.g., wheezing, shortness of breath, cough, nighttime awakenings, and missed school/work or other interference with normal activity) and pulmonary function (e.g., forced expiratory volume in 1 second) at the time of the treatment decision was unavailable in our data set. The conventional multivariate RA model and PS adjustment methods were unable to yield estimates suggesting that LTC therapy decreased exacerbation in the treated patients. The estimates from the DACC-based IV analyses demonstrated the protective effects of LTC therapy on acute asthma exacerbation.
To reduce confounding by indication, RA and IV methods have strong underlying assumptions to satisfy. RA methods assume that adjustment for measured covariates also adjusts for unmeasured covariates, while the IV approach requires specified instruments with a strong association with treatment choice and assumes that the specified instruments are unrelated to unmeasured confounders or outcomes directly.
The DACC-based IV was strongly associated with the use of LTC therapy, with F statistics ranging from 45 to 97. Instruments with an F statistic greater than 10 are considered nonweak in the IV literature (20) . The IV estimates are drawn from variations in the measured small-area LTC therapy treatment preferences that are unrelated to measured covariates, which suggests that unmeasured confounding factors may also be balanced. This reasoning is also supported by the results from the overidentification tests, which suggested that there were no direct relations between the instruments and the outcomes (35, 36) . However, it remains possible that unmeasured confounders were not distributed evenly across patients grouped by our instrument. Further validation of this assumption requires additional data sources, such as chart abstraction. It is possible, for example, that areas with high LTC treatment rates also have higher-quality health care in general than areas with low treatment rates. If this is the case, the IVestimates will be biased to reflect higher treatment benefits than the true value. Patients living in areas with greater access to primary care physicians may receive higher-quality health care. In our post hoc analysis, we found that there was no correlation between the number of primary care physicians per capita in the DACC and the use of LTC therapy, and there was only a weak and negative correlation (correlation coefficient: r ¼ À0.1) between the number of family care physicians per capita in the DACC and the ATRs (the instrument). Thus, it is unlikely that differences in the general quality of health care across DACC regions were the basis for the direction and statistical significance of the IV estimates. In addition, the difference between RA and IV estimates may be due not only to the difference in confounding control but also to the distinct treatment effect concepts estimated from each approach (1, (42) (43) (44) (45) (46) (47) . This needs to be considered in the interpretation and comparison of IVand RA estimates. RA estimators yield estimates of the average treatment effect on the treated patients, whereas IV estimators yield estimates of a ''local average treatment effect'' for ''marginal patients,'' who are a subset of patients whose treatment choices were affected by the ''instruments'' (e.g., patients who were treated in high-treatment-preference areas but would not be treated if they were in low-treatment-preference areas). When treatment effects are homogeneous in the study population or the treatment effects are heterogeneous across clinical subgroups but the treatment decision (e.g., use of LTC therapy) is unrelated to the heterogeneity, RA estimates and IV estimates both represent the average treatment effects in the whole study population and will be equivalent in the absence of confounding. However, when treatment effects are heterogeneous and the heterogeneity is associated with the treatment decision (physicians' sorting treatment toward patients who will benefit more from treatment), RA estimates of treatment benefit for treated patients will be greater than IV estimates of treatment benefit for the marginal patients (local average treatment effect), even in the absence of confounding.
In neither scenario would the IV estimate of the treatment benefit of LTC therapy exceed the RA estimate in the absence of confounding. In this study, the IV estimates demonstrated a considerably larger treatment benefit of LTC therapy for persistent asthma patients than the RA estimates. It is likely that RA estimates are biased lower than the true value by unmeasured confounding, since RA estimates are inconsistent with the established evidence from randomized clinical trials, and patients with higher severity were more likely to be treated with LTC therapy and the exact severity level was unmeasured. Though the IV estimates are consistent with the evidence from randomized clinical trials that all LTC therapies reduce acute asthma exacerbations, the estimated treatment benefit from IV analyses may be applicable only to the ''marginal patients,'' who were treated in the highertreatment-rate areas and not treated in the lower-treatmentrate areas. The ''marginal patients'' could be patients with moderate-to-severe persistent asthma who may be at higher risk of acute asthma exacerbation at baseline and may benefit more from LTC therapy in the study cohort that also included patients with mild persistent asthma.
Our persistent asthma case definition was based on the use of SABA during a 30-day period. This may have misclassified some cases of intermittent asthma with an episode of severe acute exacerbation as cases of persistent asthma. In addition, in a few special cases, initiation of LTC therapy may reduce the need for SABA to the level of intermittent asthma within 30 days among some patients with persistent asthma. Our case definition could not identify those special cases. In both situations, misclassification of cases may cause underestimation of LTC therapy treatment effects. If the extent of misclassification of asthma status varied with treatment choice, the misclassification would behave like an unmeasured confounder (18) . Our findings that the protective benefits of LTC therapy were demonstrated by the estimates from our IV analysis and not by estimates from RA methods suggest that the IV analysis may also be less subject to bias from case misclassification than RA methods (18) . The findings in our study suggest that the DACC-based IV may be a useful new tool with which to alleviate confounding by indication and assess treatment effectiveness using large observational health-care utilization databases when not all confounders are measured or can be practically determined. RA and IV methods both have strong assumptions and distinct estimates for different treatment effects. The validity of their assumptions and interpretation of their estimates may be contingent on the study population, treatments, data sources, and possible treatment effect heterogeneity. Careful application of those methods and interpretation of their estimates are needed for empirical studies.
